产品: Phospho-PI3K p85 (Tyr458)[Tyr467]/p55 (Tyr199) 抗体
货号: AF3242
来源: Rabbit
应用: WB, IHC, IF/ICC, ELISA(peptide)
反应: Human, Mouse, Rat, Monkey
预测: Zebrafish, Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus
分子量: 54kD,84kD; 84kD,54kD(Calculated).
蛋白号: P27986 | Q92569
RRID: AB_2834668

浏览相似产品>>

   规格 价格 库存
 50ul ¥1250 现货
 100ul ¥2300 现货
 200ul ¥3000 现货

货期: 当天发货

产品描述

来源:
Rabbit
应用:
WB 1:500-1:2000, IF/ICC 1:100-1:500, IHC 1:50-1:200, ELISA(peptide) 1:20000-1:40000
*The optimal dilutions should be determined by the end user.
反应:
Human,Mouse,Rat,Monkey
预测:
Zebrafish(100%), Bovine(86%), Horse(86%), Sheep(86%), Rabbit(100%), Dog(86%), Chicken(86%), Xenopus(86%)
克隆:
Polyclonal
特异性:
Phospho-PI3K p85(Tyr458)/p55(Tyr199) Antibody detects endogenous levels of PI3K p85/p55 only when phosphorylated at Tyr467(p85) or Tyr199(p55). The site Tyr467 was historically referenced as Tyr458.
RRID:
AB_2834668
引用格式: Affinity Biosciences Cat# AF3242, RRID:AB_2834668.
纯化:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

GRB 1; GRB1; p85 alpha; p85; P85A_HUMAN; Phosphatidylinositol 3 kinase associated p 85 alpha; Phosphatidylinositol 3 kinase regulatory 1; Phosphatidylinositol 3 kinase regulatory subunit alpha; Phosphatidylinositol 3 kinase regulatory subunit polypeptide 1 (p85 alpha); Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha; Phosphatidylinositol 3-kinase regulatory subunit alpha; Phosphoinositide 3 kinase regulatory subunit 1 (alpha); Phosphoinositide 3 kinase regulatory subunit 1 (p85 alpha); Phosphoinositide 3 kinase regulatory subunit 1; Phosphoinositide 3 kinase regulatory subunit polypeptide 1 (p85 alpha); PI3 kinase p85 subunit alpha; PI3-kinase regulatory subunit alpha; PI3-kinase subunit p85-alpha; PI3K; PI3K regulatory subunit alpha; Pik3r1; PtdIns 3 kinase p85 alpha; PtdIns-3-kinase regulatory subunit alpha; PtdIns-3-kinase regulatory subunit p85-alpha; DKFZp686P05226; FLJ41892; OTTHUMP00000009783; OTTHUMP00000009786; p55; p55 gamma; P55G_HUMAN; p55PIK; Phosphatidylinositol 3 kinase regulatory subunit gamma; Phosphatidylinositol 3 kinase regulatory subunit polypeptide 3; Phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55, gamma); Phosphatidylinositol 3-kinase 55 kDa regulatory subunit gamma; Phosphatidylinositol 3-kinase regulatory subunit gamma; Phosphoinositide 3 kinase regulatory subunit 3 (gamma); Phosphoinositide 3 kinase regulatory subunit 3; Phosphoinositide 3 kinase regulatory subunit polypeptide 3; Phosphoinositide 3 kinase, regulatory subunit 3 (p55, gamma); Phosphoinositide 3 kinase, regulatory subunit, polypeptide 3 (p55, gamma); PI3 kinase p85 subunit gamma; PI3-kinase regulatory subunit gamma; PI3-kinase subunit p55-gamma; PI3K regulatory subunit gamma; Pik3r3; PtdIns 3 kinase p85 gamma; PtdIns-3-kinase regulatory subunit gamma; PtdIns-3-kinase regulatory subunit p55-gamma;

抗原和靶标

免疫原:
Uniprot:
基因/基因ID:
表达特异性:
P27986 P85A_HUMAN:

Isoform 2 is expressed in skeletal muscle and brain, and at lower levels in kidney and cardiac muscle. Isoform 2 and isoform 4 are present in skeletal muscle (at protein level).

Q92569 P55G_HUMAN:

Highest levels in brain and testis. Lower levels in adipose tissue, kidney, heart, lung and skeletal muscle.

蛋白描述:
PIK3R1 is a regulatory subunit of phosphoinositide-3-kinase. Mediates binding to a subset of tyrosine-phosphorylated proteins through its SH2 domain. Acts as an adapter, mediating the association of the p110 catalytic unit of the alpha, beta and delta enzymes to the plasma membrane, where p110 phosphorylates inositol lipids. May play an additional role in the regulation of the actin cytoskeleton. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues.
蛋白序列:
MSAEGYQYRALYDYKKEREEDIDLHLGDILTVNKGSLVALGFSDGQEARPEEIGWLNGYNETTGERGDFPGTYVEYIGRKKISPPTPKPRPPRPLPVAPGSSKTEADVEQQALTLPDLAEQFAPPDIAPPLLIKLVEAIEKKGLECSTLYRTQSSSNLAELRQLLDCDTPSVDLEMIDVHVLADAFKRYLLDLPNPVIPAAVYSEMISLAPEVQSSEEYIQLLKKLIRSPSIPHQYWLTLQYLLKHFFKLSQTSSKNLLNARVLSEIFSPMLFRFSAASSDNTENLIKVIEILISTEWNERQPAPALPPKPPKPTTVANNGMNNNMSLQDAEWYWGDISREEVNEKLRDTADGTFLVRDASTKMHGDYTLTLRKGGNNKLIKIFHRDGKYGFSDPLTFSSVVELINHYRNESLAQYNPKLDVKLLYPVSKYQQDQVVKEDNIEAVGKKLHEYNTQFQEKSREYDRLYEEYTRTSQEIQMKRTAIEAFNETIKIFEEQCQTQERYSKEYIEKFKREGNEKEIQRIMHNYDKLKSRISEIIDSRRRLEEDLKKQAAEYREIDKRMNSIKPDLIQLRKTRDQYLMWLTQKGVRQKKLNEWLGNENTEDQYSLVEDDEDLPHHDEKTWNVGSSNRNKAENLLRGKRDGTFLVRESSKQGCYACSVVVDGEVKHCVINKTATGYGFAEPYNLYSSLKELVLHYQHTSLVQHNDSLNVTLAYPVYAQQRR

MYNTVWSMDRDDADWREVMMPYSTELIFYIEMDPPALPPKPPKPMTSAVPNGMKDSSVSLQDAEWYWGDISREEVNDKLRDMPDGTFLVRDASTKMQGDYTLTLRKGGNNKLIKIYHRDGKYGFSDPLTFNSVVELINHYHHESLAQYNPKLDVKLMYPVSRYQQDQLVKEDNIDAVGKKLQEYHSQYQEKSKEYDRLYEEYTRTSQEIQMKRTAIEAFNETIKIFEEQCHTQEQHSKEYIERFRREGNEKEIERIMMNYDKLKSRLGEIHDSKMRLEQDLKNQALDNREIDKKMNSIKPDLIQLRKIRDQHLVWLNHKGVRQKRLNVWLGIKNEDADENYFINEEDENLPHYDEKTWFVEDINRVQAEDLLYGKPDGAFLIRESSKKGCYACSVVADGEVKHCVIYSTARGYGFAEPYNLYSSLKELVLHYQQTSLVQHNDSLNVRLAYPVHAQMPSLCR

种属预测

种属预测:

score>80的预测可信度较高,可尝试用于WB检测。*预测模型主要基于免疫原序列比对,结果仅作参考,不作为质保凭据。

Species
Results
Score
Rabbit
100
Zebrafish
100
Horse
86
Bovine
86
Sheep
86
Dog
86
Xenopus
86
Chicken
86
Pig
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

翻译修饰 - P27986/Q92569 作为底物

Site PTM Type Enzyme
Ubiquitination
S2 Acetylation
Y12 Phosphorylation
S43 Phosphorylation
Y59 Phosphorylation
Y73 Phosphorylation
Y76 Phosphorylation
S83 Phosphorylation P17612 (PRKACA)
T86 Phosphorylation
S147 Phosphorylation
T148 Phosphorylation
T152 Phosphorylation
S154 Phosphorylation
Y203 Phosphorylation P07949 (RET)
S208 Phosphorylation
S265 Phosphorylation
S269 Phosphorylation
S279 Phosphorylation
K346 Ubiquitination
Y368 Phosphorylation P06213 (INSR)
T369 Phosphorylation
K379 Ubiquitination
K419 Ubiquitination
Y426 Phosphorylation
K438 Ubiquitination
K448 Ubiquitination
Y452 Phosphorylation
T454 Phosphorylation
K459 Sumoylation
K459 Ubiquitination
Y463 Phosphorylation
Y467 Phosphorylation
Y470 Phosphorylation
T471 Phosphorylation
T490 Phosphorylation
Y504 Phosphorylation
K506 Ubiquitination
Y508 Phosphorylation P09619 (PDGFRB)
K513 Ubiquitination
R514 Methylation
K519 Ubiquitination
R523 Methylation
Y528 Phosphorylation
K530 Acetylation
S541 Phosphorylation
Y556 Phosphorylation
K567 Ubiquitination
T576 Phosphorylation
Y580 Phosphorylation P06213 (INSR)
T603 Phosphorylation
Y607 Phosphorylation P06213 (INSR) , P12931 (SRC)
S608 Phosphorylation P42336 (PIK3CA) , P68400 (CSNK2A1)
T623 Phosphorylation
S628 Phosphorylation
S629 Phosphorylation
K633 Ubiquitination
S652 Phosphorylation Q15139 (PRKD1)
Y657 Phosphorylation
K674 Ubiquitination
Y679 Phosphorylation
Y688 Phosphorylation
S690 Phosphorylation
Site PTM Type Enzyme
Ubiquitination
K78 Ubiquitination
K106 Acetylation
K111 Ubiquitination
K114 Acetylation
K114 Ubiquitination
K155 Ubiquitination
Y163 Phosphorylation
K170 Ubiquitination
K180 Ubiquitination
Y184 Phosphorylation
S186 Phosphorylation
Y188 Phosphorylation
K191 Ubiquitination
Y195 Phosphorylation
Y199 Phosphorylation
Y202 Phosphorylation
T203 Phosphorylation
T222 Phosphorylation
K224 Ubiquitination
K238 Ubiquitination
Y260 Phosphorylation
S273 Phosphorylation
K274 Ubiquitination
K294 Ubiquitination
K299 Ubiquitination
K319 Ubiquitination
Y341 Phosphorylation P06213 (INSR)
Y373 Phosphorylation
K375 Ubiquitination
K388 Ubiquitination
Y407 Phosphorylation

研究背景

功能:

Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. Plays an important role in signaling in response to FGFR1, FGFR2, FGFR3, FGFR4, KITLG/SCF, KIT, PDGFRA and PDGFRB. Likewise, plays a role in ITGB2 signaling. Modulates the cellular response to ER stress by promoting nuclear translocation of XBP1 isoform 2 in a ER stress- and/or insulin-dependent manner during metabolic overloading in the liver and hence plays a role in glucose tolerance improvement.

翻译修饰:

Polyubiquitinated in T-cells by CBLB; which does not promote proteasomal degradation but impairs association with CD28 and CD3Z upon T-cell activation.

Phosphorylated. Tyrosine phosphorylated in response to signaling by FGFR1, FGFR2, FGFR3 and FGFR4. Phosphorylated by CSF1R. Phosphorylated by ERBB4. Phosphorylated on tyrosine residues by TEK/TIE2. Dephosphorylated by PTPRJ. Phosphorylated by PIK3CA at Ser-608; phosphorylation is stimulated by insulin and PDGF. The relevance of phosphorylation by PIK3CA is however unclear (By similarity). Phosphorylated in response to KIT and KITLG/SCF. Phosphorylated by FGR.

组织特异性:

Isoform 2 is expressed in skeletal muscle and brain, and at lower levels in kidney and cardiac muscle. Isoform 2 and isoform 4 are present in skeletal muscle (at protein level).

亚基结构:

Heterodimer of a regulatory subunit PIK3R1 and a p110 catalytic subunit (PIK3CA, PIK3CB or PIK3CD). Interacts (via SH2 domains) with CCDC88A/GIV (tyrosine-phosphorylated form); the interaction enables recruitment of PIK3R1 to the EGFR receptor, enhancing PI3K activity and cell migration. Interacts (via SH2 domain) with CSF1R (tyrosine phosphorylated). Interacts with PIK3R2; the interaction is dissociated in an insulin-dependent manner (By similarity). Interacts with XBP1 isoform 2; the interaction is direct and induces translocation of XBP1 isoform 2 into the nucleus in a ER stress- and/or insulin-dependent but PI3K-independent manner. Interacts with FER. Interacts (via SH2 domain) with TEK/TIE2 (tyrosine phosphorylated). Interacts with PTK2/FAK1 (By similarity). Interacts with phosphorylated TOM1L1. Interacts with phosphorylated LIME1 upon TCR and/or BCR activation. Interacts with SOCS7. Interacts with RUFY3. Interacts (via SH2 domain) with CSF1R (tyrosine phosphorylated). Interacts with LYN (via SH3 domain); this enhances enzyme activity (By similarity). Interacts with phosphorylated LAT, LAX1 and TRAT1 upon TCR activation. Interacts with CBLB. The SH2 domains interact with the YTHM motif of phosphorylated INSR in vitro. Also interacts with tyrosine-phosphorylated IGF1R in vitro. Interacts with CD28 and CD3Z upon T-cell activation. Interacts with IRS1 and phosphorylated IRS4, as well as with NISCH and HCST. Interacts with FASLG, KIT and BCR. Interacts with AXL, FGFR1, FGFR2, FGFR3 and FGFR4 (phosphorylated). Interacts with FGR and HCK. Interacts with PDGFRA (tyrosine phosphorylated) and PDGFRB (tyrosine phosphorylated). Interacts with ERBB4 (phosphorylated). Interacts with NTRK1 (phosphorylated upon ligand-binding). Interacts with FAM83B; activates the PI3K/AKT signaling cascade. Interacts with APPL1 and APPL2 (By similarity). Interacts with SRC.

(Microbial infection) Interacts with HIV-1 Nef to activate the Nef associated p21-activated kinase (PAK). This interaction depends on the C-terminus of both proteins and leads to increased production of HIV.

(Microbial infection) Interacts with HCV NS5A.

(Microbial infection) Interacts with herpes simplex virus 1 UL46; this interaction activates the PI3K/AKT pathway.

(Microbial infection) Interacts with herpes simplex virus 1 UL46 and varicella virus ORF12; this interaction activates the PI3K/AKT pathway.

蛋白家族:

The SH3 domain mediates the binding to CBLB, and to HIV-1 Nef.

Belongs to the PI3K p85 subunit family.

功能:

Binds to activated (phosphorylated) protein-tyrosine kinases through its SH2 domain and regulates their kinase activity. During insulin stimulation, it also binds to IRS-1.

组织特异性:

Highest levels in brain and testis. Lower levels in adipose tissue, kidney, heart, lung and skeletal muscle.

亚基结构:

Heterodimer of a regulatory subunit PIK3R3 and a p110 catalytic subunit (PIK3CA, PIK3CB or PIK3CD). Interacts with AXL.

蛋白家族:

Belongs to the PI3K p85 subunit family.

研究领域

· Cellular Processes > Transport and catabolism > Autophagy - animal.   (View pathway)

· Cellular Processes > Cell growth and death > Apoptosis.   (View pathway)

· Cellular Processes > Cell growth and death > Cellular senescence.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Signaling pathways regulating pluripotency of stem cells.   (View pathway)

· Cellular Processes > Cell motility > Regulation of actin cytoskeleton.   (View pathway)

· Environmental Information Processing > Signal transduction > ErbB signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > cAMP signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > HIF-1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > FoxO signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Phosphatidylinositol signaling system.

· Environmental Information Processing > Signal transduction > Sphingolipid signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Phospholipase D signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > mTOR signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > AMPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > TNF signaling pathway.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > EGFR tyrosine kinase inhibitor resistance.

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

· Human Diseases > Drug resistance: Antineoplastic > Platinum drug resistance.

· Human Diseases > Endocrine and metabolic diseases > Type II diabetes mellitus.

· Human Diseases > Endocrine and metabolic diseases > Insulin resistance.

· Human Diseases > Endocrine and metabolic diseases > Non-alcoholic fatty liver disease (NAFLD).

· Human Diseases > Infectious diseases: Bacterial > Bacterial invasion of epithelial cells.

· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).

· Human Diseases > Infectious diseases: Parasitic > Amoebiasis.

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Measles.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Viral carcinogenesis.

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Human Diseases > Cancers: Specific types > Colorectal cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Renal cell carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Pancreatic cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Endometrial cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Glioma.   (View pathway)

· Human Diseases > Cancers: Specific types > Prostate cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Melanoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Specific types > Acute myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Specific types > Small cell lung cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Non-small cell lung cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Central carbon metabolism in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Choline metabolism in cancer.   (View pathway)

· Organismal Systems > Immune system > Chemokine signaling pathway.   (View pathway)

· Organismal Systems > Aging > Longevity regulating pathway.   (View pathway)

· Organismal Systems > Aging > Longevity regulating pathway - multiple species.   (View pathway)

· Organismal Systems > Development > Axon guidance.   (View pathway)

· Organismal Systems > Development > Osteoclast differentiation.   (View pathway)

· Organismal Systems > Immune system > Platelet activation.   (View pathway)

· Organismal Systems > Immune system > Toll-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Natural killer cell mediated cytotoxicity.   (View pathway)

· Organismal Systems > Immune system > T cell receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > B cell receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Fc epsilon RI signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Fc gamma R-mediated phagocytosis.   (View pathway)

· Organismal Systems > Immune system > Leukocyte transendothelial migration.   (View pathway)

· Organismal Systems > Nervous system > Neurotrophin signaling pathway.   (View pathway)

· Organismal Systems > Nervous system > Cholinergic synapse.

· Organismal Systems > Sensory system > Inflammatory mediator regulation of TRP channels.   (View pathway)

· Organismal Systems > Endocrine system > Insulin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Progesterone-mediated oocyte maturation.

· Organismal Systems > Endocrine system > Estrogen signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Prolactin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Thyroid hormone signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Regulation of lipolysis in adipocytes.

· Organismal Systems > Endocrine system > Relaxin signaling pathway.

· Organismal Systems > Excretory system > Aldosterone-regulated sodium reabsorption.

· Organismal Systems > Digestive system > Carbohydrate digestion and absorption.

文献引用

1). Hu L et al. miRNA-92a-3p Regulates Osteoblast Differentiation in Patients with Concomitant Limb Fractures and Traumatic Brain Injury Through IBSP/PI3K-AKT Inhabitation. Mol Ther Nucleic Acids 2021 Feb 15;23:1345-1359. (PubMed: 33717654) [IF=10.183]

Application: WB    Species: mouse    Sample: MC3T3-E1 cells

Figure 5. |PI3K/AKT signaling is involved in IBSP-regulated osteoblast differentiation(A)Transfection of agomiRNA-92a-3p, antagomiRNA-92a-3p, agomiRNA-NC, antagomiRNA-NC, and Lipofectamine 3000 control (200 mm) in MC3T3-E1 cells for 48 h.Western blot detection of the expression of PI3K and AKT after transfection.

Application: WB    Species: Mice    Sample: MC3T3-E1 cells

Figure 5 PI3K/AKT signaling is involved in IBSP-regulated osteoblast differentiation (A) Transfection of agomiRNA-92a-3p, antagomiRNA-92a-3p, agomiRNA-NC, antagomiRNA-NC, and Lipofectamine 3000 control (200 μm) in MC3T3-E1 cells for 48 h. Western blot detection of the expression of PI3K and AKT after transfection. (B) Western blot detection of IBSP, p-PI3K, and p-AKT levels after transfection with siRNA-NC, siRNA-IBSP, and controls for 48 h. (C–G) Transfection with Lipofectamine 3000, siRNA-NC, siRNA-PI3K, or siRNA-AKT for 48 h. (C) Protein-expression levels of p-AKT, AKT, p-PI3K, and p-PI3K using western blotting. (D–G) qPCR analysis of Col1a1 (D), ALP (E), OCN (F), and Runx2 (G) expression in bone precursor cells. (H) Western blot analysis of Col1a1, ALP, OCN, and Runx2 levels 48 h after transfection. (I) Alizarin red staining of MC3T3-E1 cells 3 weeks after transfection. (J) ALP staining of MC3T3-E1 cells 2 weeks after transfection. n = 3; data are presented as mean ± SD (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; # no significance).

2). Hu L et al. miRNA-92a-3p Regulates Osteoblast Differentiation in Patients with Concomitant Limb Fractures and Traumatic Brain Injury Through IBSP/PI3K-AKT Inhabitation. Mol Ther Nucleic Acids 2021 Feb 15;23:1345-1359. (PubMed: 33717654) [IF=10.183]

3). Xi X et al. ACT001, a novel PAI-1 inhibitor, exerts synergistic effects in combination with cisplatin by inhibiting PI3K/AKT pathway in glioma. Cell Death Dis 2019 Oct 7;10(10):757 (PubMed: 31591377) [IF=9.685]

Application: WB    Species:    Sample: glioma cells

Fig. 5| ACT001 inhibits glioma cells through the PI3K/AKT signalling pathway.f The PI3K/AKT pathway was detected in glioma cells before (Con) and 24 h after PAI-039 treatment at the indicated concentrations.The results were obtained from three independent experiments, and each experiment was performed in triplicate. Data are represented as the mean ± standard error of the mean (*P < 0.05, **P < 0.01)

Application: IHC    Species: mouse    Sample: Tumour

Fig. 7| ACT001 enhances the antitumour effect of cisplatin in vivo. a Xenograft assays in the mice treated with control, ACT001, cisplatin and ACT001 + cisplatin. b Tumour volume changes in the mice treated with control, ACT001, cisplatin and ACT001 + cisplatin. c Body weight changes in the mice treated with control, ACT001, cisplatin and ACT001 + cisplatin. d IHC analysis of the PI3K, p-PI3K, AKT and p-AKT levels. Compared with the control group, the staining of p-PI3K and p-AKT was lighter in the ACT001 treatment groups. In the ACT001 + cisplatin treatment group, the staining of p-PI3K and p-AKT was lighter than in the ACT001-treated group.

4). Kang EM et al. Downregulation of microRNA-124-3p promotes subventricular zone neural stem cell activation by enhancing the function of BDNF downstream pathways after traumatic brain injury in adult rats. CNS Neurosci Ther 2022 Apr 28. (PubMed: 35481944) [IF=7.035]

5). Zhou X et al. MicroRNA miR-106a-5p targets forkhead box transcription factor FOXC1 to suppress the cell proliferation, migration, and invasion of ectopic endometrial stromal cells via the PI3K/Akt/mTOR signaling pathway. Bioengineered 2021 Dec;12(1):2203-2213. (PubMed: 34082653) [IF=6.832]

6). Dai Y et al. Ivabradine protects rats against myocardial infarction through reinforcing autophagy via inhibiting PI3K/AKT/mTOR/p70S6K pathway. Bioengineered 2021 Dec;12(1):1826-1837. (PubMed: 33975512) [IF=6.832]

Application: WB    Species: Rat    Sample: cardiac tissues

Figure 5. Effect of ivabradine on AKT/mTOR/p70S6K pathway of MI rats. (a) Representative WB bands of p-PI3K, PI3K, AKT and p-AKT. Quantification of p-PI3K (b) and PI3K (c), as normalized to β-actin. (d) Representative WB bands of mTOR, p-mTOR, p70S6K and p-p70S6K. Quantification of p-PI3K (e) and PI3K (f), as normalized to β-actin. n = 6 hearts/group. Data were expressed as mean ± SD; ##P < 0.01 vs Sham group; **P < 0.01 vs MI group; &P < 0.05 vs MI+Iva group. Abbreviations: 3-MA, 3-methyladenine; Iva, ivabradine; MI, myocardial infarction; Rap, rapamycin

7). Gao X et al. Overexpression of microRNA-107 suppressed proliferation, migration, invasion, and the PI3K/Akt signaling pathway and induced apoptosis by targeting Nin one binding (NOB1) protein in a hypopharyngeal squamous cell carcinoma cell line (FaDu). Bioengineered 2022 Mar;13(3):7881-7893. (PubMed: 35294329) [IF=6.832]

8). Liu P et al. Silencing of miR-152 contributes to DNMT1-mediated CpG methylation of the PTEN promoter in bladder cancer. Life Sci 2020 Aug 27;118311. (PubMed: 32861793) [IF=6.780]

Application: WB    Species: Mice    Sample: T24 and J82 cells

Fig. 8. MiR-152-3p/DNMT1/PTEN pathway affected the cellular progress via modulating the AKT/Ampk signaling pathway in BCa. (A-B) qPCR and western blot analysis of efficiency of PTEN over-expression in T24 and J82 cells. (C-D) CCK8 analysis of the cell viability in T24 and J82 cells. (E-F) EdU and Transwell analysis of the cell proliferation and migration in T24 and J82 cells. (G-J) Quantitative analysis of EdU and Transwell in T24 and J82 cells. (K) western blot analysis of the PI3K/p-AKT signaling pathway in T24 and J82 cells. For C-K, T24 and J82 cells were divided into four groups: pCDH-PTEN + pcDH-DNMT1 + miR-152-3p mimics, pCDH-DNMT1 + miR-152-3p mimics, pCDHNC + miR-152-3p mimics and pCDH-NC + mimics NC respectively about 48 h. β-Actin was measured as internal control of qPCR analysis. Experiments repeated three times. The *P < 0.05 and **P < 0.01in a two-tailed Student's t-test.

9). Zhu X et al. Agrimoniin sensitizes pancreatic cancer to apoptosis through ROS-mediated energy metabolism dysfunction. Phytomedicine 2022 Feb;96:153807. (PubMed: 34785107) [IF=6.656]

10). Lin X et al. Xanthotoxol suppresses non-small cell lung cancer progression and might improve patients' prognosis. Phytomedicine 2022 Jul 28;105:154364. (PubMed: 35932608) [IF=6.656]

加载更多

限制条款

产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)

产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.